CAC
SBBP

Cowen and Company’s Strongbridge Biopharma plc. SBBP Stock Holding History

Cowen and Company’s Portfolio SBBP Stock Details SBBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-154,634
Closed -$459K – 851
2021
Q2 		$459K Buy
+154,634
New +$408K 0.02% 190

Other funds holding SBBP

CC
Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Cowen and Company's SBBP Position: Q3 2021 in Review

Cowen and Company sold out of Strongbridge Biopharma plc. (SBBP) in Q3 2021, closing a stake of 154,634 shares — an estimated $459K sold.

Cowen and Company first reported a position in SBBP in Q2 2021 and held it in 1 quarter. The position peaked at $459K in Q2 2021. 49 funds tracked by Wall St. Rank hold SBBP as of Q3 2021.

  • Cowen and Company reported no remaining Strongbridge Biopharma plc. position as of Q3 2021 after selling out during the quarter.
  • Cowen and Company sold 154,634 Strongbridge Biopharma plc. shares in Q3 2021, an estimated $459K.
  • Cowen and Company first reported a position in Strongbridge Biopharma plc. in Q2 2021 and held it in 1 quarter.
  • Cowen and Company's Strongbridge Biopharma plc. position peaked at $459K in Q2 2021.
  • 49 funds tracked by Wall St. Rank held Strongbridge Biopharma plc. as of Q3 2021.

Based on Cowen and Company's 13F filing for Q3 2021, filed 12 Nov 2021.